

Литература

1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. *Eur Heart J*, 2016, 37(42): 3232-3245.
2. Russian Statistical Yearbook 2016. Российский статистический ежегодник. 2016.
3. Бойцов С.А. Актуальные направления и новые данные в эпидемиологии и профилактике неинфекционных заболеваний. *Терапевтический архив*, 2016, 88(1): 4-10.
4. Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. *Eur Heart J*, 2009, 30: 1046-1056.
5. Pereira M, Azevedo A, Lunet N, Carreira H, O'Flaherty M, Capewell S, Bennett K. Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008. *Circ Cardiovasc Qual Outcomes*, 2013, 6: 634-642.
6. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol*, 2010, 39(2): 504-518.
7. Метельская В.А., Шальнова С.А., Деев А.Д., Перова Н.В., Гомыранова Н.В., Литинская О.А., Евстифеева С.Е., Артамонова Г.В., Гагагонова Т.М., Гринштейн Ю.И., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Ильин В.А., Либис Р.А., Минаков А.В., Невзорова В.А., Недогода С.В., Романчук С.А., Ротарь О.П. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). *Профилактическая медицина*, 2016, 19(1): 15-23.
8. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*, 2011, 86: 304-314.
9. National Institute for Health and Care Excellence. NICE Public Health Guidance 25. June 2010. <https://www.nice.org.uk/guidance/ph25>.

10. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*, 2010, 376: 1670–1681.
11. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cifková R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Miličić D, Moore D, Nicolaidis E, Oganov R, Pajak A, Pogossova N, Reiner Z, Stagno M, Störk S, Tokgözoğlu L, Vucic D, EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol*, 2016, 23: 636-648.
12. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*, 2016, 37(39): 2999-3058.
13. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*, 2014, 129(25 Suppl 2): S1-45.
14. Liu K, Daviglius ML, Loria CM, Colangelo LA, Spring B, Moller AC, Lloyd-Jones DM. Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. *Circulation*, 2012, 125: 996–1004.
15. Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart

disease mortality in the United States of America. Bull World Health Org, 2010, 88: 120–130.

16. Mozaffarian D, Capewell S. United Nations' dietary policies to prevent cardiovascular disease. BMJ, 2011, 343: d5747.

17. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013, 34(38): 2949–3003.

18. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med, 1976. 295(7): 369–377.

19. Мясников А.Л. Гипертоническая болезнь и атеросклероз. М.: Медицина, 1965.

20. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol, 2009, 29(4): 431–438. PMID: 2740366.

21. Сергиенко И.В. История появления статинов. Атеросклероз и дислипидемии, 2011, 1: 57–66.

22. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006, 295(13): 1556–1565.

23. Finn AV, Nakano M, Narula J et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol, 2010, 30(7): 1282–1292.

24. Fishbein MC. The vulnerable and unstable atherosclerotic plaque. Cardiovasc Pathol, 2010, 19(1): 6–11.

25. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol, 2006, 47(8 Suppl): 7–12.

26. Руководство по кардиологии. В 4 томах (под ред. Е.И. Чазова). В.В. Кухарчук, В.Н. Титов. Атеросклероз и дислипидемии. Т. 3: 15–58. М.: Практика, 2014.

27. Bentzon JF, Otsuka F, Virmani R et al. Mechanisms of plaque formation and rupture. Circ Res, 2014, 114(12): 1852–1866.

28. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation, 2003, 107(16): 2072–2075.

29. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. *Arterioscler Thromb Vasc Biol*, 2005, 25(10): 2054-2061.
30. Casscells W, Hassan K, Vaseghi MF et al. Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses. *Am Heart J*, 2003, 145(5): 813-820.
31. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. *Атеросклероз и дислипидемии*, 2012, 4(9): 4-52.
32. Климов А.Н., Никульчева Н.Г. Обмен липидов и липопротеидов и его нарушения. Руководство для врачей. Издание третье. СПб.: 1999.
33. Нозадзе Д.Н., Сергиенко И.В., Балахонова Т.В. и соавт. Связь уровня липопротеин-ассоциированной фосфолипазы А2 с категориями риска сердечно-сосудистых заболеваний. *Кардиология*, 2014, 3: 57-63.
34. Нозадзе Д.Н., Семенова А.Е., Каминная В.И. и соавт. Липопротеин ассоциированная фосфолипаза А2 – новая позиция в системе стратификации риска? *Атеросклероз и дислипидемии*, 2011, 1: 41-47.
35. Сафарова М.С., Ежов М.В. Липопротеид(а) как фактор риска сердечно-сосудистых заболеваний: современное состояние вопроса. *Атеросклероз и дислипидемии*, 2011, 1: 6-18.
36. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*, 2010, 31(23): 2844-2853. PMID: 3295201.
37. Климов А.Н. Причины и условия развития атеросклероза. Превентивная кардиология. Под ред. Г.И. Косицкого. М.: Медицина, 1977.
38. Schiffrin EL. The endothelium of resistance arteries: physiology and role in hypertension. *Prostaglandins Leukot Essent Fatty Acids*, 1996, 54(1): 17-25.
39. Haller H. Endothelial function. General considerations. *Drugs*, 1997, 53(Suppl 1): 1-10.
40. Luscher TF. Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. *Lung*, 1990, 168(Suppl): 27-34.

41. Modena MG, Bonetti L, Coppi F et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. *J Am Coll Cardiol*, 2002, 40(3): 505-510.
42. Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. *Physiol Rev*, 1998, 78(1): 53-97.
43. Hansson GK, Hermansson A. The immune system in atherosclerosis. *Nat Immunol*, 2011, 12(3): 204-212.
44. Wever RM, Luscher TF, Cosentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. *Circulation*, 1998, 97(1): 108-112.
45. Ishii H, Tezuka T, Ishikawa H et al. Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. *Blood*, 2003, 101(12): 4765-4774.
46. Нозадзе Д.Н., Рвачева А.В., Казначеева Е.И. и соавт. Моноциты в развитии и дестабилизации атеросклеротической бляшки. *Атеросклероз и дислипидемии*, 2013, 2: 23-37.
47. Сергиенко И.В., Нозадзе Д.Н., Казначеева Е.И. Влияние хемокинов на формирование атеросклеротического поражения за счет регулирования функции лейкоцитов. *Атеросклероз и дислипидемии*, 2012, 3: 37-47.
48. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2^{-/-} mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature*, 1998, 394(6696): 894-897.
49. Mosig S, Rennert K, Krause S et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14⁺CD16⁺ monocytes in detoxification of oxidized LDL. *FASEB J*, 2009, 23(3): 866-874.
50. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. *Immunol Rev*, 2007, 218: 126-134.
51. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. *J Mol Med (Berl)*, 2003, 81(1): 4-19.

52. Zhou Z, Subramanian P, Sevilimis G et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. *Cell Metab*, 2011, 13(5): 592-600.
53. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol*, 2005, 5(12): 953-964.
54. Varin A, Gordon S. Alternative activation of macrophages: immune function and cellular biology. *Immunobiology*, 2009, 214(7): 630-641.
55. Brocheriou I, Maouche S, Durand H et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. *Atherosclerosis*, 2011, 214(2): 316-324.
56. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity*, 2010, 32(5): 593-604.
57. Gratchev A, Kzhyshkowska J, Kothe K et al. Mphi1 and Mphi2 can be repolarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. *Immunobiology*, 2006, 211(6-8): 473-486.
58. Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. *Front Physiol*, 2012, 3: 44. PMID: 3307136.
59. Merad M, Sathe P, Helft J et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol*, 2013, 31: 563-604. PMID: 3853342.
60. Choi JH, Do Y, Cheong C et al. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. *J Exp Med*, 2009, 206(3): 497-505. PMID: 2699134.
61. Weber C, Meiler S, Doring Y et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. *J Clin Invest*, 2011, 121(7): 2898-2910. PMID: 3223829.
62. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. *Nat Rev Immunol*, 2006, 6(7): 508-519.
63. Prasad KS, Andre P, Yan Y et al. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. *Curr Opin Hematol*, 2003, 10(5): 356-361.

64. Nguyen VT, Benveniste EN. Involvement of STAT-1 and its family members in interferon- γ induction of CD40 transcription in microglia/macrophages. *J Biol Chem*, 2000, 275(31): 23674-23684.
65. Mallat Z, Heymes C, Ohan J et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. *Arterioscler Thromb Vasc Biol*, 1999, 19(3): 611-616.
66. Huber SA, Sakkinen P, David C et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. *Circulation*, 2001, 103(21): 2610-2616.
67. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T-cell immunity in atherosclerosis. *Trends Cardiovasc Med*, 2007, 17(4): 113-118.
68. Nishikawa H, Kato T, Tawara I et al. IFN- γ controls the generation/activation of CD4⁺ CD25⁺ regulatory T cells in antitumor immune response. *J Immunol*, 2005, 175(7): 4433-4440.
69. Zhou X, Caligiuri G, Hamsten A et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. *Arterioscler Thromb Vasc Biol*, 2001, 21(1): 108-114.
70. Drechsler M, Megens RT, van Zandvoort M et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. *Circulation*, 2010, 122(18): 1837-1845.
71. Soehnlein O, Zernecke A, Eriksson EE et al. Neutrophil secretion products pave the way for inflammatory monocytes. *Blood*, 2008, 112(4): 1461-1471. PMID: 3400540.
72. Zhang Z, Cherryholmes G, Chang F et al. Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. *Eur J Immunol*, 2009, 39(11): 3181-3194. PMID: 3076219.
73. Massberg S, Grahl L, von Bruehl ML et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med*, 2010, 16(8): 887-896.
74. Cole JE, Navin TJ, Cross AJ et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. *Proc Natl Acad Sci U S A*, 2011, 108(6): 2372-2377. PMID: 3038746.

75. Kinoshita M, Okada M, Hara M et al. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. *Arterioscler Thromb Vasc Biol*, 2005, 25(9): 1858-1863.
76. Sun J, Sukhova GK, Wolters PJ et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. *Nat Med*, 2007, 13(6): 719-724.
77. Leskinen MJ, Kovanen PT, Lindstedt KA. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells—a potential mechanism for the weakening and rupture of atherosclerotic plaques. *Biochem Pharmacol*, 2003, 66(8): 1493-1498.
78. Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. *Curr Opin Lipidol*, 2004, 15(5): 567-573.
79. Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardio-metabolic diseases. *Nat Rev Cardiol*, 2015, 12(11): 643-658.
80. Boytcov SA, Urazalina SJ, Kukharchuk VV et al. Subclinical arterial wall damage in patients at low to moderate cardiovascular risk. *Acta Cardiol*, 2015, 70(3): 274-281.
81. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). *Annu Rev Immunol*, 2009, 27: 165-197. PMID: 2734407.
82. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. *Arterioscler Thromb Vasc Biol*, 1995, 15(5): 551-561. PMID: 2924812.
83. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation*, 2007, 116(16): 1832-1844.
84. Tellides G, Tereb DA, Kirkiles-Smith NC et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. *Nature*, 2000, 403(6766): 207-211.
85. Ward MR, Pasterkamp G, Yeung AC et al. Arterial remodeling. Mechanisms and clinical implications. *Circulation*, 2000, 102(10): 1186-1191.
86. Amento EP, Ehsani N, Palmer H et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. *Arterioscler Thromb*, 1991, 11(5): 1223-1230.

87. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. *J Leukoc Biol*, 2007, 82(6): 1375-1381.
88. Johnson JL, George SJ, Newby AC et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. *Proc Natl Acad Sci U S A*, 2005, 102(43): 15575-15580. PMID: 1266110.
89. Домбровский А.Л., Сергиенко И.В., Аншелес А.А. и соавт. Содержание эндотелиальных прогениторных клеток фенотипа CD 34+/CD 133+/CD 309+, а также факторов ангиогенеза в крови у больных ИБС. *Терапевт*, 2015, 7: 23-29.
90. Lolmede K, Campana L, Vezzoli M et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. *J Leukoc Biol*, 2009, 85(5): 779-787.
91. Rohde E, Malischnik C, Thaler D et al. Blood monocytes mimic endothelial progenitor cells. *Stem Cells*, 2006, 24(2): 357-367.
92. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell*, 2002, 109(5): 625-637. PMID: 2826110.
93. Abbott JD, Huang Y, Liu D et al. Stromal cell-derived factor-1 alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. *Circulation*, 2004, 110(21): 3300-3305.
94. Dentelli P, Rosso A, Balsamo A et al. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. *Blood*, 2007, 109(10): 4264-4271.
95. Lataillade JJ, Domenech J, Le Bousse-Kerdiles MC. Stromal cell-derived factor-1 (SDF-1)\CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. *Eur Cytokine Netw*, 2004, 15(3): 177-188.

96. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. *Trends Immunol*, 2007, 28(7): 299-307. PMID: 2952492.
97. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med*, 2003, 9(11): 1370-1376.
98. Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med*, 2004, 10(8): 858-864.
99. Zhang Q, Yin H, Liu P et al. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. *Exp Biol Med* (Maywood), 2010, 235(9): 1082-1092.
100. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. *Cardiovasc Res*, 2008, 78(3): 413-421.
101. De Boer HC, Verseyden C, Ulfman LH et al. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. *Arterioscler Thromb Vasc Biol*, 2006, 26(7): 1653-1659.
102. Langer H, May AE, Daub K et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. *Circ Res*, 2006, 98(2): e2-10.
103. Lev EI, Estrov Z, Aboulfatova K et al. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. *Thromb Haemost*, 2006, 96(4): 498-504.
104. Xu Q. Stem cells and transplant arteriosclerosis. *Circ Res*, 2008, 102(9): 1011-1024.
105. Zeng L, Xiao Q, Margariti A et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. *J Cell Biol*, 2006, 174(7): 1059-1069. PMID: 2064396.
106. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. *Ann Intern Med*. 1998, 129(12): 1050-1060.
107. Kolodgie FD, Gold HK, Burke AP et al. Intraplaque hemorrhage and progression of coronary atheroma. *N Engl J Med*, 2003, 349(24): 2316-2325.

108. Bodary PF, Gu S, Shen Y et al. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*, 2005, 25(8): e119-122.
109. Epstein SE, Stabile E, Kinnaird T et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. *Circulation*, 2004, 109(23): 2826-2831.
110. Mallat Z, Corbaz A, Scoazec A et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. *Circ Res*, 2001, 89(7): E41-45.
111. Kuhlencordt PJ, Chen J, Han F et al. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. *Circulation*, 2001, 103(25): 3099-3104.
112. Doherty TM, Asotra K, Fitzpatrick LA et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. *Proc Natl Acad Sci U S A*, 2003, 100(20): 11201-11206. PMID: 208734.
113. Otsuka F, Finn AV, Virmani R. Do vulnerable and ruptured plaques hide in heavily calcified arteries? *Atherosclerosis*, 2013, 229(1): 34-37.
114. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. *Arterioscler Thromb Vasc Biol*, 2006, 26(7): 1423-1430.
115. Wexler L, Brundage B, Crouse J et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. *Circulation*, 1996, 94(5): 1175-1192.
116. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc Biol*, 2004, 24(7): 1161-1170.
117. Bostrom K, Watson KE, Horn S et al. Bone morphogenetic protein expression in human atherosclerotic lesions. *J Clin Invest*, 1993, 91(4): 1800-1809. PMID: 288161.

118. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. *Arterioscler Thromb Vasc Biol*, 2001, 21(12): 1998-2003.
119. Golledge J, McCann M, Mangan S et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. *Stroke*, 2004, 35(7): 1636-1641.
120. Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? *Cardiovasc Res*, 2000, 45(3): 736-746.
121. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. *Curr Opin Lipidol*, 2003, 14(5): 469-475.
122. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. *Arterioscler Thromb Vasc Biol*, 2002, 22(9): 1370-1380.
123. Kim YM, Talanian RV, Li J et al. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). *J Immunol*, 1998, 161(8): 4122-4128.
124. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. *Arterioscler Thromb Vasc Biol*, 2003, 23(9): 1553-1558.
125. Zerneck A, Bot I, Djalali-Talab Y et al. Protective role of CXC receptor 4/ CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. *Circ Res*, 2008, 102(2): 209-217.
126. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. *Nat Rev Immunol*, 2010, 10(6): 427-439.
127. Esmon CT. The impact of the inflammatory response on coagulation. *Thromb Res*, 2004, 114(5-6): 321-327.
128. Klein NJ, Shennan GI, Heyderman RS et al. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. *J Cell Sci*, 1992, 102(Pt 4): 821-832.

129. Conway EM, Van de Wouwer M, Pollefeyt S et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. *J Exp Med*, 2002, 196(5): 565-577. PMID: 2193995.
130. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. *J Biol Chem*, 1989, 264(34): 20705-20713.
131. Burstein SA. Platelets and cytokines. *Curr Opin Hematol*, 1994, 1(5): 373-380.
132. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. *Curr Vasc Pharmacol*, 2011, 9: 258-270.
133. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. *Eur Heart J*, 2013, 34: 1826-1833.
134. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. *Clin Chem*, 2011, 57: 482-489.
135. Cooney MT, Dudina A, D'Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? *Circulation*, 2010, 122: 300-310.
136. Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Зубарева М.Ю., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Мартынов А.И., Небиеридзе Д.В., Покровский С.Н., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Чазова И.Е., Шальнова С.А., Шапошник

И.И., Кухарчук В.В. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии, 2017, 3: 5-22.

137. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372: 2387-2397.

138. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*, 2017, 376(18): 1713-1722.

139. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*, 2017, 390(10106): 1962-1971.

140. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*, 2014, 64: 485-494.

141. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. American Association Of Clinical Endocrinologists And American College Of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease - executive summary. *Endocr Pract*, 2017, 23(4): 479-497.

142. Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). *Diabetol Metab Syndr*, 2017, 9: 53.

143. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*, 2014, 129(25 Suppl 2): S76–S99.

144. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*, 2013, 368: 1279–1290.

145. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation*, 1999, 99: 779–785.

146. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB, Wang M, Siscovick DS. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. *Ann Intern Med*, 2013, 158: 515–525.

147. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*, 2013, 1: CD004816.
148. Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. *Lancet*, 2003, 361: 1149–1158.
149. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*, 2004, 364: 685–696.
150. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA*, 2001, 285: 1711–1718.
151. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. *N Engl J Med*, 2004, 350(15): 1495-1504.
152. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA- ACS randomized trial. *J Am Coll Cardiol*, 2007, 49: 1272-1278.
153. Shepherd J, Kastelein JJ, Bittner V et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. *J Am Coll Cardiol*, 2008, 51(15): 1448-1454.
154. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. *Curr Med Res Opin*, 2002, 18: 220-228.

155. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*, 2006, 355(6): 549-559.

156. Newman CB et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. *Am J Cardiol*, 2003 Sep 15, 92(6): 670-676.

157. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J*, 2010, 160: 785-794e10.

158. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*, 2003, 34: 154-156.

159. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. *Annu Rev Pharmacol Toxicol*, 2014, 54: 273-293.

160. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372: 1489-1499.

161. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372: 1500-1509.

162. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. *Atherosclerosis*, 1993, 101: 61-68.

163. Triglyceride Coronary Disease Genetics, Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani

- NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet*, 2010, 375: 1634–1639.
164. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA*, 2007, 298: 309–316.
165. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*, 2007, 298: 299–308.
166. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol*, 2013, 61: 427–436.
167. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. *N Engl J Med*, 2014, 371: 32–41.
168. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. *Eur J Cardiovasc Prev Rehabil*, 2009, 16: 121–137.
169. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. *Circ Res*, 2013, 112: 1405–1408.
170. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Aversa M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J*, 2013, 34: 3478–3490a.
171. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacol Ther*, 2010, 126: 314–345.

172. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*, 2010, 375: 1875–1884.

173. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis*, 2011, 217: 492–498.

174. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. *J Cardiovasc Pharmacol*, 2011, 57: 267–272.

175. Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? *Eur Heart J*, 2012, 33: 562–563.

176. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*, 2007, 370: 1829–1839.

177. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. *Eur Heart J*, 1998, 19: 1434–1503.

178. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*, 2006, 113: 791–798.

179. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. *N Engl J Med*, 2012, 366: 321–329.

180. Giang KW, Björck L, Novak M, Lappas G, Wilhelmsen L, Torén K, Rosengren A. Stroke and coronary heart disease: predictive power of standard risk factors into old age—long-term cumulative risk study among men in Gothenburg, Sweden. *Eur Heart J*, 2013, 34: 1068–1074.

181. Wilhelmsen L, Svärdsudd K, Eriksson H, Rosengren A, Hansson PO, Welin C, Odén A, Welin L. Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden. *J Intern Med*, 2011, 269: 441–451.
182. Reiner Z. Primary prevention of cardiovascular disease with statins in the elderly. *Curr Atheroscler Rep*, 2014, 16: 420.
183. Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol*, 2013, 62: 2090–2099.
184. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*, 2002, 360: 1623–1630.
185. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). *Circulation*, 2007, 115: 700–707.
186. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). *Circulation*, 1997, 96: 4211–4218.
187. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*, 2002, 360: 7–22.
188. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia*, 2003, 46: 760–765.

189. Chillaron JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. *Metabolism*, 2014, 63: 181–187.
190. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA*, 2004, 292: 1307–1316.
191. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol*, 2005, 46: 1405–1410.
192. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA*, 2012, 308: 1024–1033.
193. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio G. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. *Circulation*, 2011, 123: 1622–1632.
194. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. *Am J Med*, 2014, 127: 987–1000.
195. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. *Eur Heart J*, 2015, 36: 2446–2453.
196. Finegold JA, Francis DP. What proportion of symptomatic side-effects in patients taking statins are genuinely caused by the drug? A response to letters. *Eur J Prev Cardiol*, 2015, 22: 1328–1330.

197. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. *Circ Cardiovasc Qual Outcomes*, 2013, 6: 390–399.
198. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. *Cardiovasc Drugs Ther*, 2005, 19: 403–414.
199. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. *Am J Cardiol*, 2006, 97(8A): 32–43.
200. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. *Am J Geriatr Pharmacother*, 2012, 10: 264–271.
201. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology*, 2004, 126: 1287–1292.
202. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. *Am J Med Sci*, 2005, 329: 62–65.
203. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. *J Hepatol*, 2015, 63: 705–712.
204. Law M, Rudnicka AR. Statin safety: a systematic review. *Am J Cardiol*, 2006, 97(8A): 52–60.